Samonigg H - Search Results

1

Combined treatment of metastatic osteosarcoma of the spine.

Bauernhofer T, Stöger H, Kasparek AK, Ploner F, Kuss I, Pieber TR, Kotz R, Samonigg H. Bauernhofer T, et al. Among authors: samonigg h. Oncology. 1999 Nov;57(4):265-8. doi: 10.1159/000012058. Oncology. 1999. PMID: 10575309 Review.

2

Combination therapy of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose folinic acid in patients with advanced breast cancer: a phase I-II study (preliminary results).

Samonigg H, Stöger H, Bauernhofer T, Schmid M, Kasparek AK, Kuss I, Kaul M, Heberle U, Vieder L, Dusleag J, et al. Samonigg H, et al. Am J Clin Oncol. 1990;13 Suppl 1:S44-7. Am J Clin Oncol. 1990. PMID: 2291457 Clinical Trial.

3

The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.

Schippinger W, Regitnig P, Bauernhofer T, Ploner F, Hofmann G, Krippl P, Wehrschütz M, Lax S, Carney W, Neumann R, Wernecke KD, Samonigg H. Schippinger W, et al. Among authors: samonigg h. Oncol Rep. 2004 Jun;11(6):1331-6. Oncol Rep. 2004. PMID: 15138574

4

Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.

Schippinger W, Holub R, Dandachi N, Bauernhofer T, Samonigg H. Schippinger W, et al. Among authors: samonigg h. Oncology. 2006;70(4):290-3. doi: 10.1159/000094890. Epub 2006 Aug 4. Oncology. 2006. PMID: 16899982

5

Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer.

Samonigg H, Stöger H, Kasparek AK, Schmid M, Dusleag J, Pfeiffer K, Smola M, Steindorfer P, Lechner P. Samonigg H, et al. Cancer Chemother Pharmacol. 1991;27(6):477-80. doi: 10.1007/BF00685163. Cancer Chemother Pharmacol. 1991. PMID: 2013118

6

4'-O-tetrahydropyranyl-doxorubicin in advanced breast cancer: a phase II study.

Samonigg H, Kasparek AK, Stöger H, Schmid M, Eber B, Stark G, Weinrauch V, Pfeiffer K, Smola M, Steindorfer P, et al. Samonigg H, et al. Cancer Chemother Pharmacol. 1990;26(4):293-6. doi: 10.1007/BF02897233. Cancer Chemother Pharmacol. 1990. PMID: 2369794

7

A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients.

Stöger H, Bauernhofer T, Schmid M, Ploner F, Moser R, Derstvenscheg E, Steindorfer P, Wilders-Truschnig M, Kuss I, Samonigg H. Stöger H, et al. Among authors: samonigg h. Cancer Chemother Pharmacol. 1994;35(2):174-8. doi: 10.1007/BF00686643. Cancer Chemother Pharmacol. 1994. PMID: 7987997 Clinical Trial.

8

Sequential treatment of recurrent mesenteric desmoid tumor.

Bauernhofer T, Stöger H, Schmid M, Smola M, Gürtl-Lackner B, Höfler G, Ranner G, Reisinger E, Samonigg H. Bauernhofer T, et al. Among authors: samonigg h. Cancer. 1996 Mar 15;77(6):1061-5. Cancer. 1996. PMID: 8635124 Review.

9

A double-blind randomized-phase II trial comparing immunization with antiidiotype goat antibody vaccine SCV 106 versus unspecific goat antibodies in patients with metastatic colorectal cancer.

Samonigg H, Wilders-Truschnig M, Kuss I, Plot R, Stöger H, Schmid M, Bauernhofer T, Tiran A, Pieber T, Havelec L, Loibner H. Samonigg H, et al. J Immunother. 1999 Nov;22(6):481-8. J Immunother. 1999. PMID: 10570746 Clinical Trial.

10

Seminoma metastases mimicking primary pancreatic cancer.

Wehrschütz M, Stöger H, Ploner F, Hofmann G, Wolf G, Höfler G, Krippl P, Samonigg H. Wehrschütz M, et al. Among authors: samonigg h. Onkologie. 2002 Aug;25(4):371-3. doi: 10.1159/000066057. Onkologie. 2002. PMID: 12232490

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

210 results

Search Page